Meeting
2014 Genitourinary Cancers Symposium
Evidence for circulating tumor cell (CTC) alkaline phosphatase (AP) expression in men with bone-metastatic castration-resistant prostate cancer (CRPC) during abiraterone acetate treatment.
Authors
Andrew J. Armstrong
Duke University, Durham, NC
Andrew J. Armstrong , Rhonda Lynn Bitting , Gabor Kemeny , Daniel J. George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 178)
DOI
10.1200/jco.2014.32.4_suppl.178
Abstract #
178
Poster Bd #
K21
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
Circulating tumor cell (CTC) detection, N-terminal androgen (AR) characterization, and PTEN loss in metastatic or advanced castration resistant prostate cancer (CRPC).
First Author: Shidong Jia
Poster
2023 ASCO Genitourinary Cancers Symposium
Characteristics of long-term responder (LTR) patients (pts) treated with androgen-receptor signaling inhibitors (ARSI) as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC): Real-world evidence from four high-volume institutions.
First Author: Orazio Caffo
Poster
2020 Genitourinary Cancers Symposium
Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Santosh Gupta
Poster
2016 ASCO Annual Meeting
Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.
First Author: Mary-Ellen Taplin